Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AstraZeneca Reveals Designs for Cambridge Headquarters

Published: Friday, July 18, 2014
Last Updated: Wednesday, July 23, 2014
Bookmark and Share
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.

The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre.

Key features of the site include:

• Science at the heart – the high technology labs on the site will be separated from other work spaces by glass walls to promote ‘visible science’, ensuring scientific innovation is the primary focus for all staff, both in R&D and other functions.

• Fostering collaboration –the site will feature a number of open spaces and thoroughfares to encourage collaboration not only within AstraZeneca, but also with the wider scientific community within the CBC and beyond.

• Reflecting the character of the City – the unique characteristics of Cambridge’s historic centre have influenced the shape of the buildings. The site will be low rise and will include a central courtyard reflecting the colleges of Cambridge University.

• An environmental build –AstraZeneca is seeking Building Research Establishment Environmental Assessment Methodology (BREAAM) Excellent status for the site, which will feature labs that represent best practice in low energy design and the largest ground source heat pump in Europe. “Green Roofs” will also be installed across the majority of the site.

Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development at AstraZeneca said: “We are very excited to be able to reveal the plans for our new site in Cambridge today. Our aim is to create an open, welcoming and vibrant centre that will inspire our teams and partners to push the boundaries of scientific innovation.”

The new site will bring together AstraZeneca’s small molecule and biologics research and development activity, opening up opportunities to exploit the promise of biologics and small molecule combinations. The CBC will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm. MedImmune already employs around 500 people at Granta Park, to the south east of the city.

“With our combined AstraZeneca and MedImmune portfolios we are already uniquely positioned to explore the promise of combination therapies in transforming the way patients are treated,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “Our new Global Research Centre in Cambridge will see AstraZeneca and MedImmune scientists working side by side to advance science in our core therapeutic areas. This will support and strengthen our focus on combining the expertise across our business to develop new ways to treat patients and tackle the significant unmet need that exists in areas such as oncology.”

Stefan Marbach, Senior Partner at Herzog & de Meuron, the architects selected to design the new site in Cambridge, said: “In designing the new building we made reference to the historical colleges in central Cambridge, which are typically low-rise buildings enclosing a central courtyard. The building's proportions draw on this, as well as the open public access to the courtyard. The whole structure is connected in a single loop, providing short connections within the building and modern, innovative workspaces that support collaborative working. The ‘saw-tooth’ roof, which carries on through to the facade, aims to unify the appearance of the building and give it a distinctive character.”

In advance of the new site coming online in late 2016, around 70 AstraZeneca staff have already relocated to interim facilities in Cambridge, at the Melbourn Science Park, Cambridge Science Park and Granta Park. By the end of 2014 approximately 300-400 AstraZeneca staff will have relocated to the city, to cement important relationships with other members of the Cambridge life science community.

Mene Pangalos continued: “As we carry on our work to get the new site up and running, our focus is on continuing to build important relationships with partners in the local bioscience community. With up to 400 staff relocating to the city by the end of the year, and with the range of exciting collaborations we have underway, Cambridge is already an important part of our innovation footprint here in the UK alongside our sites in the North West, which will continue to be important elements of our UK presence.”

Recent collaborations AstraZeneca has entered into in Cambridge include:

• In May 2014 AstraZeneca announced its intention to collaborate with the Medical Research Council (MRC) Laboratory of Molecular Biology to fund a range of pre-clinical research projects, aimed at better understanding the biology of disease.

• In March 2014 AstraZeneca and the MRC announced the creation of the AstraZeneca MRC UK Centre for Lead Discovery, which will sit within the new AstraZeneca site at the Cambridge Biomedical Campus and see AstraZeneca and MRC-supported researchers working side-by-side.

• In February 2014 AstraZeneca entered into a collaboration with the Cancer Research UK Cambridge Institute, to locate up to 60 of the Company’s scientists in the Institute’s state of the art labs on the CBC over the next three years. The first of AstraZeneca’s scientists have already moved into the Cambridge Institute labs.

Designs for AstraZeneca’s new site are being made available today as part of a public consultation2 for the local community, ahead of submission of a detailed planning application in Autumn 2014. AstraZeneca expects to begin the build of the new site in early 2015.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca, Lilly to Study Immuno-Oncology Combination
This collaboration sets out to assess the efficacy of a combinatorial treatment in patients with advanced solid state tumors.
Monday, June 01, 2015
AstraZeneca and Harvard Stem Cell Institute Collaborate
Collaboration will develop the use of stem cells for diabetes research.
Wednesday, March 25, 2015
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca and the Broad Institute Collaborate
Partnership to advance discovery of antibacterial and antiviral agents.
Tuesday, September 11, 2012
AstraZeneca to Provide UK Academics with Access to Compound Library
Their groundbreaking new collaboration with the Medical Research Council (MRC) will see the company providing the UK academic sector with access to 22 drugs.
Friday, December 09, 2011
Scientific News
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Vital Protein in Healthy Fertilization Process Identified
Researchers at the National Institutes of Health have discovered a protein that plays a vital role in healthy egg-sperm union in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!